Breast Cancer Risk and Hormone Replacement Therapy
Author Information
Author(s): Dinger Juergen C, Heinemann Lothar AJ, Möhner Sabine, Thai Do Minh, Assmann Anita
Primary Institution: Centre for Epidemiology & Health Research Berlin
Hypothesis
Does the use of different hormone replacement therapy (HRT) formulations affect breast cancer risk in women?
Conclusion
The breast cancer risk associated with HRT use is relatively small and does not vary significantly across different formulations.
Supporting Evidence
- The adjusted overall risk estimate for breast cancer associated with current or past use of HRT was 1.2.
- Many established breast cancer risk factors significantly modified the effect of HRT on breast cancer risk.
- No substantial difference in breast cancer risk was observed between HRT containing conjugated equine estrogens or medroxyprogesterone acetate and other formulations.
Takeaway
Using hormone replacement therapy might slightly increase the risk of breast cancer, but the difference isn't very big and varies little between different types of therapy.
Methodology
A case-control study was conducted using data from cancer registries and tumor centers in Germany, comparing breast cancer cases with matched controls.
Potential Biases
Potential biases include diagnostic suspicion bias and exposure misclassification.
Limitations
The study is observational and subject to biases such as self-selection and recall bias, which may affect the results.
Participant Demographics
The study included women diagnosed with breast cancer and matched controls, with a mean age of 54.6 for cases and 50.6 for controls.
Statistical Information
P-Value
1.2 (1.1–1.3)
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website